When was UAS Labs founded?

UAS Labs was founded in 1979 and raised its 1st funding round 34 years after it was founded.

Where is UAS Labs located?

UAS Labs is headquartered in Wausau, United States.

How many employees does UAS Labs have?

As of Mar 31, 2026, the latest employee count at UAS Labs is 59.

Is UAS Labs a funded company?

UAS Labs is a funded company, having raised a total of $31.7M across 4 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Apr 2013.

How much is UAS Labs worth?

The last known valuation of UAS Labs was $***** as of Jun 10, 2020.

When was the latest funding round of UAS Labs?

UAS Labs' latest funding was a $***** Series B round on Feb 06, 2019, with participation from 0 investor.

Where does UAS Labs rank among its competitors?

UAS Labs ranks 45th amongst 756 active competitors, of which 42 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Shenshi Technology, which secured $114M in Dec, 2025.

Who are the top competitors of UAS Labs?

UAS Labs' top competitors include Pfizer, Pharmaron and Boehringer Ingelheim. Among them, Shenshi Technology secured the most recent funding round in December, 2025.

UAS Labs - 2026 Company Profile, Funding & Competitors

Q: Is UAS Labs an acquired company?

UAS Labs got acquired by Chr. Hansen on Jun 10, 2020.

Company Details

Website: uaslabs.com
Email ID: *****@uaslabs.com
Phone Number: +1 **********

Key Metrics

Founded Year

1979

Location

Wausau, United States

Stage

Acquired

Total Funding

$31.7M in 4 rounds

Latest Funding Round

Series B, Feb 06, 2019, $*****

Last Known Valuation

$***** as on Jun 10, 2020

Investors

Greyrock Capital Group

Ranked

45^th among 756 active competitors

Employee Count

59 as on Mar 31, 2026

Investment & Acquisitions

Nebraska Cultures & 1 more

Similar Companies

Pfizer & 815 more

Exit Details

Acquired by Chr. Hansen (Jun 10, 2020)

View UAS Labs' full profile

UAS Labs is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Uas Laboratories Llc CIN: 461445982 , United States, Active	Nov 15, 2012	-	206 (As on Dec 31, 2020)	-

UAS Labs got acquired by Chr. Hansen on Jun 10, 2020 at an acquisition amount of $*****.

Click here to take a look at UAS Labs's acquisition in detail

UAS Labs has raised a total funding of $31.7M over 4 rounds. Its first funding round was on Apr 2013. UAS Labs has 1 institutional investor.

Here is the list of recent funding rounds of UAS Labs:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 06, 2019	7364603	Series B	7085781	8493237	6773841	6204349
Feb 10, 2017	4955974	Series B	2462034	7750374	2624632	4709799
Apr 2013	3231638	Series A	5884091	8350931	Greyrock Capital Group	6428262

Access funding benchmarks and valuations. Sign up today!

View details of UAS Labs's funding rounds and investors

UAS Labs' employee count trend

UAS Labs has 59 employees as of Mar 26. Here is UAS Labs's employee count trend over the years:

Uncover UAS Labs' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of UAS Labs include Pfizer, Pharmaron and Boehringer Ingelheim. Here is the list of Top 10 competitors of UAS Labs, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Berkshire Hathaway, Alcor Fund & 16 others	79/100
2nd	Pharmaron 2003, Beijing (China), Public	Suite of drug discovery and development services for small molecules	$320M	Gl-investment, Legend Capital & 11 others	76/100
3rd	Boehringer Ingelheim 1885, Ingelheim am Rhein (Germany), Funding Raised	Provider of generic drugs and clinical research services	-	Amgen Business Development, Sanderling Ventures ... & 1 others	64/100
4th	Lonza 1897, Basel (Switzerland), Acquired	Provider of CDMO services to pharma, biotech, and specialty ingredient markets	-	Defense.gov, EDBI & 4 others	59/100
5th	Tyra 2018, Carlsbad (United States), Public	Developer of cancer resistance therapies	$156M	Boxer Capital, RA Capital Management & 6 others	59/100
6th	LabConnect 2002, Johnson City (United States), Series A	Provider of laboratory testing, clinical ttrial research, and biopharma functional services	$29.2M	Broadoak Capital Partners, ABS Capital & 5 others	58/100
7th	Shenshi Technology 2019, Beijing (China), Series C	Developer of AI-driven platform and tools for scientific research and development	$255M	Source Code Capital, Baidu Venture Capital ... & 22 others	58/100
8th	Clearsynth 2009, Mumbai (India), Series A	CDMO focused on manufacturing of pharmaceutical small molecules and analytical research services	$4.81M	SIDBI Venture Capital, Tulip Diagnostics & 7 others	57/100
9th	Matchpoint Therapeutics 2021, Cambridge (United States), Series A	Provider of small molecular medicine development and analytics services	$100M	Access Industries, Sanofi Ventures & 4 others	55/100
10th	Evergreen Theragnostics 2019, Jersey City (United States), Acquired	Provider of radiopharmaceuticals manufacturing and regulatory services	$75.9M	Petrichor, Novacapital & 4 others	52/100
45th	UAS Labs 1979, Wausau (United States), Acquired	Provider of clinical research and probiotic fermentation services	$31.7M	Greyrock Capital Group	41/100